“[Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in Italy]” (2016) Farmeconomia. Health economics and therapeutic pathways, 17(2S), pp. 37–48. doi:10.7175/fe.v17i2S.1231.